HER2-targeted PET imaging and therapy of hyaluronan-masked HER2-overexpressing breast cancer
2019
Human epidermal growth factor receptor 2 (HER2) is a biomarker in breast cancer and its overexpression is required to initiate therapies using HER2-targeted antibodies. Although trastuzumab is one of the most effective therapeutic antibodies in HER2-overexpressing breast cancer, a significant number of patients do not benefit from this therapy due to inherent or acquired resistance mechanisms. One reported mechanism of resistance is the steric hindering effect caused by the polymeric complex formed between hyaluronan and CD44; thus, preventing trastuzumab from binding to HER2. Hyaluronan/CD44 not only contributes as an obstacle for trastuzumab to bind HER2, but it is also involved in HER2 internalization. In this study, we used zirconium-89 (89Zr)-labeled trastuzumab immunoPET to investigate whether degradation of hyaluronan can resensitize HER2-overexpressing breast cancer cells to trastuzumab. Targeted degradation of endogenously produced hyaluronan and inhibition of its synthesis were achieved by treat...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
50
References
11
Citations
NaN
KQI